UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 71

Sortiert nach

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

Clinical cancer research, 2011-11, Vol.17 (22), p.6958-6962

2011

Volltextzugriff (PDF)

Antagonists of PD-1 and PD-L1 in Cancer Treatment

Seminars in oncology, 2015-08, Vol.42 (4), p.587-600

2015

Volltextzugriff (PDF)

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

Annals of the rheumatic diseases, 2017-01, Vol.76 (1), p.43

2017

Volltextzugriff (PDF)

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event

Journal of clinical oncology, 2019-10, Vol.37 (30), p.2714-2718

2019

Volltextzugriff (PDF)

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

Seminars in arthritis and rheumatism, 2018-12, Vol.48 (3), p.553-557

2018

Volltextzugriff (PDF)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Journal for immunotherapy of cancer, 2016-08, Vol.4 (1), p.50-50, Article 50

2016

Volltextzugriff (PDF)

PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison

Clinical cancer research, 2017-08, Vol.23 (16), p.4938-4944

2017

Volltextzugriff (PDF)

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Clinical cancer research, 2020-02, Vol.26 (3), p.545-551

2020

Volltextzugriff (PDF)

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis

World journal of gastroenterology : WJG, 2017-03, Vol.23 (11), p.2023-2028

2017

Volltextzugriff (PDF)

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors

Clinical cancer research, 2021-05, Vol.27 (9), p.2571-2583

2021

Volltextzugriff (PDF)

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

The oncologist (Dayton, Ohio), 2017-06, Vol.22 (6), p.627-630

2017

Volltextzugriff (PDF)

Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy

Clinical cancer research, 2017-06, Vol.23 (12), p.3168-3180

2017

Volltextzugriff (PDF)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

Journal for immunotherapy of cancer, 2018-10, Vol.6 (1), p.99-11, Article 99

2018

Volltextzugriff (PDF)

BRAF‐V600 mutational status affects recurrence patterns of melanoma brain metastasis

International journal of cancer, 2017-06, Vol.140 (12), p.2716-2727

2017

Volltextzugriff (PDF)

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

Journal of translational medicine, 2015-07, Vol.13 (1), p.214, Article 214

2015

Volltextzugriff (PDF)

Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade

Journal of translational medicine, 2024-03, Vol.22 (1), p.241-12, Article 241

2024

Volltextzugriff (PDF)

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

Nature reviews. Clinical oncology, 2014-01, Vol.11 (1), p.24

2014

Volltextzugriff (PDF)

Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding

Science immunology, 2020-07, Vol.5 (49)

2020

Volltextzugriff (PDF)

Cardiovascular toxicities associated with immune checkpoint inhibitors

Cardiovascular research, 2019-04, Vol.115 (5), p.854-868

2019

Volltextzugriff (PDF)

Nivolumab: targeting PD-1 to bolster antitumor immunity

Future oncology (London, England), 2015-05, Vol.11 (9), p.1307-1326

2015

Volltextzugriff (PDF)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer

Journal for immunotherapy of cancer, 2022-07, Vol.10 (7), p.e004434

2022

Volltextzugriff (PDF)

Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade

Journal for immunotherapy of cancer, 2023-12, Vol.11 (12), p.e007463

2023

Volltextzugriff (PDF)

Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis

Rheumatic & musculoskeletal diseases open, 2022-09, Vol.8 (2), p.e002511

2022

Volltextzugriff (PDF)

Shorter survival and later stage at diagnosis among unmarried patients with cutaneous melanoma: A US national and tertiary care center study

Journal of the American Academy of Dermatology, 2020-10, Vol.83 (4), p.1012-1020

2020

Volltextzugriff (PDF)

Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer

JAMA neurology, 2016-08, Vol.73 (8), p.928

2016

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Aktive Filter

ThemaCancer Therapies

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(71)

Sprache

Englisch
(71)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

Antagonists of PD-1 and PD-L1 in Cancer Treatment

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

BRAF‐V600 mutational status affects recurrence patterns of melanoma brain metastasis

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding

Cardiovascular toxicities associated with immune checkpoint inhibitors

Nivolumab: targeting PD-1 to bolster antitumor immunity

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer

Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade

Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis

Shorter survival and later stage at diagnosis among unmarried patients with cutaneous melanoma: A US national and tertiary care center study

Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer

Aktive Filter

Suchergebnisse filtern